Field Medical has closed a $35m series B financing round for advancing the development of the FieldForce pulsed field ablation platform.
This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors.
The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company’s clinical and regulatory capabilities. It brings Field Medical’s total funding to $75m.
BioStar Capital founder and senior managing director Dr Louis Cannon said: 鈥淔ield Medical’s transformative technology is doing what few companies dare to do 鈥� tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency.
鈥淭heir physician-led team brings the right insight, and their FieldForce platform brings the right tools.鈥�
In 2024, the FieldForce ablation system received breakthrough device designation and was selected for the US Food and Drug Administration (FDA) TAP Pilot programme for ventricular tachycardia (VT).
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe next-generation system has been designed for transmural lesion creation and provides a new approach to VT ablation.
It remains an investigational device, limited to research use under US law.
Field Medical founder and CEO Dr Steven Mickelsen said: 鈥淰T is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need.
鈥淲e are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.鈥�
In conjunction with this growth funding, Field Medical has updated its board of directors.
The board includes Dr Steven Mickelsen, the company’s founder and CEO; Mark Wisniewski, CFO of Enterra Medical; and Marlou Janssen, board member at Field Medical, Sonion, Acarix, EBAMed and Inspiration Healthcare.
Additional members comprise surgeon and entrepreneur Alexei Mlodinow and Cue Growth founding partner Ben Cannon.
